ABSTRACT
Objective To evaluate the clinical curative effect and methods for recurring NPC with treatment of intracavitary radiotherapy after interventional chemotherapy. Methods 32 cases of recurring NPC were divided into two groups, each of which consisted of 16 cases. Group one was treated with intracavitary chemotherapy plus intracavitary radiotherapy. On the third day after interventional chemotherapy, the first intracavitary radiotherapy was performed (5 Gy) and the second treatment was done next day. Group two was only performed with intracavitary radiotherapy. The dose and interval were the same. The time of re examination was two weeks later. Results In the first group, clinical symptoms were improved, local swelling lymph nodes were shrunk, secretion on the nasopharyngeal surface was hardly left or disappeared. Tumours were shrunk and atrophy. On the intracavitary radiotherapy group, clinical symptoms changed a little, except the secretion on the mass surface was reduced. The white blood counts of the two groups showed no difference and there were no functional changes of liver, kidney and digestive system in the interventional group. Conclusions It is a new and effective therapy to treat recurring NPC with interventional chemotherapy plus intracavitary radiotherapy.
ABSTRACT
Objective To evaluate the clinical effect of trans reformed catheter infusion for treatment of fallopian tube obstrution with Yuebei infertility.Methods 86 cases of fallopian tube obstrution were recanalized by trans reformed catheter infusion. Results 86 cases with 169 obstructive fallopian tube altogether, among them 119 were recanalized by once of this procedure, 33 by twice. The total effective rate was 89.9%. 86 cases were all followed up including 39 cases got pregnant after once of this procedure, 18 were pregnant after twice of the performance. The total pregnancy rate reached 66.3%. Conclusions Trans reformed catheter infusion therapy is a safe and effective method to treat infertility resulted from fallopian tube obstruction.